Pages that link to "Q46630469"

The following pages link to Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain (Q46630469):

Displaying 33 items.

• Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems (Q24235450) (← links)
• Interventions to reduce weight gain in schizophrenia (Q24243093) (← links)
• Management of antipsychotic-related weight gain (Q24610124) (← links)
• Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis (Q27692023) (← links)
• World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects (Q34315836) (← links)
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance (Q34640811) (← links)
• Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis (Q34661011) (← links)
• Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial (Q34761216) (← links)
• Management of atypical antipsychotic drug-induced weight gain: focus on metformin (Q34983478) (← links)
• Successful use of add - on topiramate for antipsychotic - induced weight gain (Q35993196) (← links)
• Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. (Q36034676) (← links)
• Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. (Q36232038) (← links)
• Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review (Q36377890) (← links)
• Interventions for the metabolic syndrome in schizophrenia: a review (Q36401248) (← links)
• Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications (Q36577866) (← links)
• Efficacy of add-on topiramate therapy in psychiatric patients with weight gain (Q37118263) (← links)
• Antipsychotic induced weight gain in schizophrenia:mechanisms and management (Q37160453) (← links)
• Pharmacological management of atypical antipsychotic-induced weight gain. (Q37165503) (← links)
• Schizophrenia, obesity, and antipsychotic medications: what can we do? (Q37226376) (← links)
• Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? (Q37356492) (← links)
• Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain (Q37710237) (← links)
• A systematic review of metformin to limit weight-gain with atypical antipsychotics (Q37854834) (← links)
• Treatment of Co-Morbid Mental Illness in Primary Care: How to Minimize Weight Gain, Diabetes, and Metabolic Syndrome (Q37889896) (← links)
• Modulation of ion channels in clinical psychopharmacology: adults and younger people (Q37960095) (← links)
• BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. (Q38826206) (← links)
• Antipsychotic-associated weight gain: management strategies and impact on treatment adherence (Q41546064) (← links)
• Comment: Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain (Q43001768) (← links)
• [Efficacy of behavioural lifestyle interventions for weight management of psychiatric patients]. (Q45209540) (← links)
• Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial (Q46565043) (← links)
• Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials (Q47947938) (← links)
• Topiramate and Metformin Are Effective Add-On Treatments in Controlling Antipsychotic-Induced Weight Gain: A Systematic Review and Network Meta-Analysis (Q59805368) (← links)
• The effects of antipsychotic medications on microbiome and weight gain in children and adolescents. (Q64939436) (← links)
• Topiramate-induced weight loss depends on level of intellectual disability in patients with epilepsy (Q88388758) (← links)